1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Global Biopolar Disorder Therapeutics Market 2015-2019

Global Biopolar Disorder Therapeutics Market 2015-2019

  • December 2015
  • -
  • Infiniti Research Limited
  • -
  • 94 pages

About bipolar disorder therapeutics
Bipolar disorder is a psychological disorder characterized by intermittent mood swings. The individual suffering with this disorder experiences extreme poles of either mania or depression or both. The disorder severely affects the personal, social, and professional life of an individual. The symptoms usually include drastic changes in mood, either as a manic episode or a depressive episode. There is no complete cure for the disorder. Atypical antipsychotics, mood stabilizers, and antidepressants are being widely used in for treatment. It is considered as a lifelong disease and the discontinuation of the medication can lead to relapse of the condition.

Technavio's analysts forecast the global bipolar disorder therapeutics market to grow at a CAGR of 2.24% over the period 2014-2019.

Covered in this report
The report covers the present scenario and growth prospects of the global bipolar disorder therapeutics market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of bipolar disorder.

Technavio's report, Global Bipolar Disorder Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, APAC, and EMEA; it also covers the landscape of the global bipolar disorder therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions
- Americas
- APAC
- EMEA


Key vendors
- Allergan
- AstraZeneca
- BMS
- Eli Lilly
- GlaxoSmithKline
- Janssen Pharmaceuticals

Other prominent vendors
- AbbVie
- Abital Pharma
- Astellas
- Convergence Pharmaceuticals
- D Pharm
- Delpor
- Gedeon Richter
- H. Lundbeck
- Intra-Cellular Therapies
- Novartis
- Noven Pharmaceuticals
- Omeros Corporation
- Otsuka
- Pfizer
- PNBDevCo
- Reviva Pharmaceuticals
- SK Biopharmaceuticals
- Sunovion Pharmaceutical

Key market driver
- Increase in prevalence of bipolar disorder
- For a full, detailed list, view our report

Key market challenge
- Use of alternative therapies
- For a full, detailed list, view our report

Key market trend
- Rise in public awareness
- For a full, detailed list, view our report


Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Table Of Contents

Global Biopolar Disorder Therapeutics Market 2015-2019
PART 01: Executive summary
- Highlights
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
- Key market highlights
PART 05: Disease overview
- Understanding the disorder
- Types of bipolar disorder
- Causes
- Signs and symptoms
- Management
- Self-help
- Epidemiology
PART 06: Pipeline analysis
- ITI-007
- FK949E
- PROCYCLOX
- RP5603
- CNV1061436
- LY2979165
- DP-VPA
- SKL-PSY
- PGW-5
- DLP-114
- DLP-115
- Small molecule targeting GPR78
PART 07: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 08: Market segmentation by drug class
- Mood stabilizers
- Anticonvulsants
- Atypical antipsychotics
- Antidepressant drugs
- Anti-anxiety drugs
PART 09: Market segmentation by mechanism of action
- Selective serotonin reuptake inhibitors
- Serotonin-norepinephrine reuptake inhibitors
- Tricyclic antidepressants
- Monoamine oxidase inhibitors
- Benzodiazepines
- Beta blockers
- Others
PART 10: Geographical segmentation
- Global bipolar disorder therapeutics market by geographical segmentation 2014-2019
- Bipolar disorder therapeutics market in Americas
- Bipolar disorder therapeutics market in EMEA
- Bipolar disorder therapeutics market in APAC
PART 11: Market drivers
- Increase in prevalence of bipolar disorder
- High unmet need
- Increase in RandD
PART 12: Impact of drivers
PART 13: Market challenges
- Use of alternative therapies
- Lack of availability of standard diagnostic methods
- Limited awareness of disease
- Increase in patent expiries
PART 14: Impact of drivers and challenges
PART 15: Market trends
- Rise in public awareness
- Patient assistance programs
- Strategic alliances
PART 16: Vendor landscape
- Competitive scenario
- Market share analysis 2014
- Other prominent vendors
PART 17: Key vendor analysis
- Allergan
- AstraZeneca
- BMS
- Eli Lilly
- GSK
- Janssen Pharmaceuticals
PART 18: Appendix
- List of abbreviatios
PART 19: Explore Technavio

Exhibit 01: Product offerings
Exhibit 02: Signs and symptoms of bipolar disorder
Exhibit 03: Signs and symptoms of mania
Exhibit 04: Signs and symptoms of depression
Exhibit 05: Treatment options for bipolar disorder
Exhibit 06: Medications for treating bipolar disorder
Exhibit 07: Global bipolar disorder therapeutics market: Pipeline portfolio
Exhibit 08: Global bipolar disorder therapeutics market 2014-2019 ($ millions)
Exhibit 09: Five forces analysis
Exhibit 10: Segmentation of global bipolar disorder therapeutics market by drug class
Exhibit 11: Global bipolar disorder therapeutics market segment by geography 2014
Exhibit 12: Bipolar disorder therapeutics market revenue by geography 2014-2014 ($ millions)
Exhibit 13: Bipolar disorder therapeutics market in Americas 2014-2019 ($ millions)
Exhibit 14: Bipolar disorder therapeutics market in EMEA 2014-2019 ($ millions)
Exhibit 15: Bipolar disorder therapeutics market in APAC 2014-2019 ($ millions)
Exhibit 16: Impact of drivers
Exhibit 11: Common disorders that co-exist with bipolar disorder
Exhibit 17: Impact of drivers and challenges
Exhibit 18: Market share analysis of global bipolar disorder therapeutics market 2014
Exhibit 19: YoY growth rate of major bipolar disorder drugs 2014-2019 ($ millions)
Exhibit 20: Bristol-Myers Squibb: YoY growth and revenue generated from net product sales of Abilify 2011-2014 ($ millions)
Exhibit 21: Bristol-Myers Squibb: Percentage share of Abilify in US and non-US region based on revenue 2014
Exhibit 22: Bristol-Myers Squibb: Key takeaways
Exhibit 23: AstraZeneca: YoY growth and revenue generated from net product sales of Seroquel XR 2011-2014 ($ millions)
Exhibit 24: AstraZeneca: Revenue generated from sales of Seroquel XR by region 2014 ($ millions)
Exhibit 25: AstraZeneca: YoY growth and revenue generated from net product sales of Seroquel IR 2011-2014 ($ millions)
Exhibit 26: AstraZeneca: Key takeaways
Exhibit 27: Janssen Pharmaceuticals: YoY growth and revenue generated from net product sales of Risperdal Consta 2011-2014 ($ millions)
Exhibit 28: Janssen Pharmaceuticals: Key takeaways
Exhibit 29: Eli Lilly: YoY growth and revenue generated from net product sales of Zyprexa 2011-2014 ($ millions)
Exhibit 30: Eli Lilly: Key takeaways
Exhibit 31: GlaxoSmithKline: YoY growth and revenue generated from net product sales of Lamictal 2011-2014 ($ millions)
Exhibit 32: GlaxoSmithKline: Revenue generated from sales of Lamictal by region 2014 ($ millions)
Exhibit 33: GlaxoSmithKline: Key takeaways
Exhibit 34: Allergan: Key takeaways
Exhibit 35: Allergan: Business segmentation by product revenue 2014
Exhibit 36: Allergan: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 37: Allergan: Geographical segmentation by revenue 2014
Exhibit 38: AstraZeneca: Business segmentation by revenue 2014
Exhibit 39: AstraZeneca: Business segmentation by revenue 2013 and 2014
Exhibit 40: AstraZeneca: Geographical segmentation by revenue 2014
Exhibit 41: BMS: Segmentation by revenue 2014
Exhibit 42: BMS: Segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 43: BMS: Geographical segmentation by revenue 2014
Exhibit 44: Lilly: Business segmentation by revenue 2014
Exhibit 45: Eli Lilly: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 46: Eli Lilly: Geographical segmentation by revenue 2014
Exhibit 47: GSK: Business segmentation by revenue 2014
Exhibit 48: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 49: GSK: Geographical segmentation by revenue 2014
Exhibit 50: Janssen Pharmaceuticals: Key therapeutic areas

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Bipolar disorder (BPD)  - Market Insights, Epidemiology and Market Forecast-2023

Bipolar disorder (BPD)  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Bipolar disorder (BPD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Bipolar disorder (BPD) fo ...

Bipolar disorder (BPD)  - Epidemiology Forecast To 2023

Bipolar disorder (BPD)  - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight “Bipolar disorder (BPD)  - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Bipolar disorder (BPD)  in seven major markets (US, France, Germany, Italy, ...

Bipolar Disorder (Manic Depression)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Bipolar Disorder (Manic Depression)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

  • $ 2000
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Report, “Bipolar Disorder (Manic Depression)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.